LLVM powers the core development tools, operating systems, and most applications at Apple Computer, where it long ago ...

Government contractors are facing significant changes to their compliance obligations this year; taken together, these developments signal ...

TikTok super app now books hotels, streams full songs, tracks FIFA World Cup scores, and is pursuing a fintech license in ...

Q.ANT successfully demonstrated a diffusion model and a recurrent neural network on its second-generation Native Processing Unit (NPU) at ISC High Performance 2026 in Hamburg. This proves that Q.ANT’s ...

Adaptable generalists with relevant, cross-disciplinary experience are becoming the most valuable hires for the future of ...

Instagram is expanding its Your Algorithm feature to the main feed, enabling users to view and modify the topics that drive their content recommendations The update utilizes large language models to ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Erik Steiger discusses the operational pain ...

Wall Street is chasing AI momentum and leaving much of the market in the dust, but the smaller stocks are keeping up. The Invesco S&P 500 Equal Weight ETF, which counts every S&P 500 stock as if they ...

007 First Light is introducing a fresh start for James Bond, and it could prove to be the gift that keeps on giving for franchise fans. The combat basics of 007 First Light revolve around the core ...

What’s unusual today is the degree of divergence between individual stocks and the cap-weighted index. The single most damaging decision most investors make during periods of falling stock market ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an ...

(RTTNews) - Kymera Therapeutics, Inc. (KYMR) announced that the first patient has been dosed in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective degrader of STAT6, in ...